Nexterone (Amiodarone In Dextrose,Iso-Osm) Patent Expiration, LOE Window & CMS Spending

Nexterone (Amiodarone In Dextrose,Iso-Osm) by Baxter Healthcare: FDA Orange Book LOE 2033-02-27, 9 AB generics, $503K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBaxter Healthcare
FDA Application & PathwayN022325 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-02-27
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$503K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$503K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.